PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 80 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $321,325 | -39.5% | 30,986 | -16.4% | 0.00% | -100.0% |
| Q2 2023 | $530,857 | +191.2% | 37,071 | +45.2% | 0.00% | – |
| Q1 2023 | $182,284 | -35.2% | 25,530 | +1.8% | 0.00% | – |
| Q4 2022 | $281,442 | +5.0% | 25,084 | +3.6% | 0.00% | – |
| Q3 2022 | $268,000 | +27.6% | 24,220 | -2.8% | 0.00% | – |
| Q2 2022 | $210,000 | -25.3% | 24,930 | +20.9% | 0.00% | – |
| Q1 2022 | $281,000 | -37.4% | 20,625 | -9.7% | 0.00% | -100.0% |
| Q4 2021 | $449,000 | -37.7% | 22,849 | +1.7% | 0.00% | 0.0% |
| Q3 2021 | $721,000 | -23.8% | 22,473 | -19.6% | 0.00% | 0.0% |
| Q2 2021 | $946,000 | +44.2% | 27,938 | +60.0% | 0.00% | 0.0% |
| Q1 2021 | $656,000 | +21.9% | 17,463 | +7.8% | 0.00% | 0.0% |
| Q4 2020 | $538,000 | -11.8% | 16,194 | -2.6% | 0.00% | 0.0% |
| Q3 2020 | $610,000 | +11.5% | 16,629 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $547,000 | +27.5% | 16,629 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $429,000 | -16.2% | 16,629 | +1.2% | 0.00% | 0.0% |
| Q4 2019 | $512,000 | – | 16,437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
| Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
| Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
| 683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
| Western Standard LLC | 109,055 | $920,000 | 0.70% |
| MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
| Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
| StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
| Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |